News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Warns On Possible Heart, Diabetes Risk With Prostate Cancer Drugs Including Abbott Laboratories (ABT)' Lupron, AstraZeneca PLC (AZN)'s Zoladex, Sanofi-Aventis (France) (SASY.PA)'s Eligard, and Pfizer Inc. (PFE)'s Synarel



10/21/2010 6:33:59 AM

Wall Street Journal -- WASHINGTON (Dow Jones)--New warnings about the potential risk of cardiovascular problems and diabetes will be added to the labels of hormone-therapy drugs that are used to treat prostate cancer, the Food and Drug Administration said Wednesday.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES